vimarsana.com

Page 6 - பிரிவு ஆஃப் மருத்துவ புற்றுநோயியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Scientists identify distinct sub-types of angiosarcomas to allow for targeted treatment

Scientists identify distinct sub-types of angiosarcomas to allow for targeted treatment A new study led by clinician-scientists from the National Cancer Centre Singapore (NCCS), with collaborators from research institutions worldwide, has found that angiosarcomas have unique genomic and immune profiles which allow them to be classified into three different subtypes. With this new and improved classification system, patients can be treated using a personalized-medicine approach and it will encourage the development of novel treatments. Angiosarcomas, a type of cancer that forms in the lining of the blood and lymph vessels, are more commonly found in Asia making up 7% of all sarcoma diagnoses. Angiosarcomas are aggressive and can spread to various regions of the body and most often occur on the scalp and face.

Study identifies distinct sub-types of aggressive tumours to allow for targeted treatment

Angiosarcomas are clinically aggressive tumours that are more prevalent in Asian populations Study led by Singapore clinician-scientists has found a way to classify angiosarcomas into three subtypes, allowing for more targeted treatment, better outcomes for patients and the development of new therapies Findings were published in The Journal of Clinical Investigation in October this year Singapore, 29 December 2020 - A new study led by clinician-scientists from the National Cancer Centre Singapore (NCCS), with collaborators from research institutions worldwide, has found that angiosarcomas have unique genomic and immune profiles which allow them to be classified into three different subtypes. With this new and improved classification system, patients can be treated using a personalised-medicine approach and it will encourage the development of novel treatments.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.